{"id":"W2763669093","doi":"10.1200/jco.2017.35.15_suppl.5560","title":"The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum resistant ovarian cancer (OC).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Chemotherapy; Regimen; Oncology; Randomization; Placebo; Ovarian cancer; Population; Cohort; Progression-free survival; Chemotherapy regimen; Surgery; Cancer; Randomized controlled trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00198605,0.0006168836,0.001229884,0.0001817691,0.0003544881,0.0006475556,0.0003576255,0.0007316557,0.006423302],"category_scores_gemma":[0.00124213,0.0002202173,0.0008742648,0.0002543026,0.0003230799,0.0004221409,0.0005635195,0.0013549,0.001023763],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004712213,"about_ca_system_score_gemma":0.001071882,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005007818,"about_ca_topic_score_gemma":0.001778982,"domain_scores_codex":[0.9995458,0.0002409379,0.00003312291,0.00007414573,0.00004502393,0.00006091713],"domain_scores_gemma":[0.9995769,0.0001402053,0.00006843357,0.00002942061,0.00003100664,0.0001541242],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4961166,0.01988668,0.03387379,0.003266396,0.00185779,0.001154236,0.0002659704,0.003835354,0.03564412,0.002239789,0.01887861,0.3829806],"study_design_scores_gemma":[0.6522024,0.2072549,0.05811341,0.000424587,0.001747873,0.00184998,0.0001143068,0.00296493,0.008346788,0.002412022,0.06451955,0.00004920818],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9346864,0.01126358,0.003507819,0.002144485,0.0003865191,0.02395179,0.008344026,0.0001093307,0.01560609],"genre_scores_gemma":[0.9591659,0.003949193,0.00453383,0.002657055,0.0003373225,0.01391255,0.00684364,0.00004023433,0.008560304],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006423302,"threshold_uncertainty_score":0.02148807,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.15170531100399,"score_gpt":0.5279345403881305,"score_spread":0.3762292293841404,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}